Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

19.93 +0.05 (+0.28%)
Streaming Delayed Price Updated: 10:27 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
From Genmab
Via Business Wire
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Why Genmab's Stock Is Trading Higher Today
Genmab A/S (NASDAQ:GMAB) shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA has granted accelerated approval to... 
Via Benzinga
Exposures Product Safety
Why Seagen's Stock Is Trading Higher Today
Seagen (NASDAQ:SGEN) shares are trading higher after the company, along with Genmab A/S (NASDAQ: GMAB), announced the FDA has granted accelerated approval to TIVDAKTM... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S’ (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The... 
Via Benzinga
Exposures Product Safety
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its... 
Via Benzinga
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
From Seagen Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2021
Upgrades For Signet Jewelers Ltd (NYSE: 
Via Benzinga
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
From Genmab A/S
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021
Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021
Upgrades Canaccord Genuity upgraded the previous rating for Precision Drilling Corp (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
Genmab Stock Flashes Healthy RS Rating
Genmab stock just cleared an important benchmark with an RS Rating upgrade from 79 to 82. Is Genmab on your watchlist? 
Via Investor's Business Daily
Genmab A/S (GMAB) Q2 2021 Earnings Call Transcript
GMAB earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs. Highlights: Microsoft (NASDAQ:MSFT) was the biggest company by market cap to set a new 52-week high... 
Via Benzinga
2 Biotech Stocks to Buy for Outsized Gains
Biotech companies’ success in responding to the COVID-19 pandemic by rapidly developing COVID-19 medicines and vaccines exemplified the sector’s importance and garnered significant investor attention. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
From Genmab A/S
Via Business Wire
Genmab - Janssen's Darzalex Wins Positive Opinion In Europe For Two New Indications
Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to ... 
Via Benzinga
Genmab A/S (GMAB) Q1 2021 Earnings Call Transcript
GMAB earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.